Andepram is a selective inhibitor of serotonin (5-HT) re-uptake. The inhibition of 5-HT re-uptake is the only likely mechanism of action explaining the pharmacological and clinical effects of escitalopram. Andepram has no or low affinity for a number of receptors including 5-HT1A, 5-HT2, DA D1 and D2 receptors, α1-, α2-, β-adrenoceptors, histamine H1, muscarine cholinergic, benzodiazepine and opioid receptors.
Andepram is used for Depressive illness, Generalized anxiety disorder, Obsessive-compulsive disorder, Social anxiety disorder
Andepram is also used to associated treatment for these conditions: Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
|Other Names||(S)-Citalopram, Escitalopram, Escitalopramum|
Escitalopram exhibits relatively low protein binding at approximately 55-56%.
|Therapeutic Class||SSRIs & related anti-depressant drugs|
|Manufacturer||Radiant Pharmaceuticals Ltd|
|Last Updated:||June 23, 2021 at 11:20 am|
Table Of contents
Adults: The initial dose of Andepram Oxalate is 10 mg once daily. (A fixed dose trial of Andepram Oxalate demonstrated the effectiveness of both 10 mg and 20 mg of Andepram Oxalate, but failed to demonstrate a greater benefit of 20 mg over 10 mg.)
If the dose is increased to 20 mg, this should occur after a minimum of one week.
Panic disorder: Adult over 18 years, initially 5 mg once daily increased to 10 mg daily after 7 days; max. 20 mg daily; elderly initially half adult dose, lower maintenance dose may be sufficient;
Social anxiety disorder: Adult over 18 years, initially 10 mg once daily adjusted after 2-4 weeks; usual dose 5-20 mg daily.
Elderly: A single oral dose of 10 mg/day is the recommended dose for most elderly patients. Administered in excess recommended dose has not been yet established.
Andepram is well tolerated by most people. The most commonly reported side-effects of Andepram are nausea, insomnia, problems with ejaculation, drowsiness, increased sweating and fatigue. Most of the side-effects experienced by patients taking Andepram are mild and go away with continued treatment and usually do not cause patients to stop taking Andepram.
During marketing of escitalopram and other SSRIs and SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with escitalopram. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.
Andepram should not be started until 2 weeks after stopping an MAOI. Conversely, an MAOI should not be started until at least a week after escitalopram or related antidepressant has been stopped.
- Avoid alcohol. The combined use of alcohol with psychotropic medications should be avoided.
- Take with or without food. The absorption is unaffected by food.
Volume of Distribution
Andepram appears to distribute extensively into tissues, with an apparent volume of distribution of approximately 12-26 L/kg.
The elimination half-life of escitalopram is 27-32 hours, though this is increased by approximately 50% in the elderly and doubled in patients with reduced hepatic function. The elimination half-life of escitalopram's primary metabolite, S-desmethylcitalopram, is approximately 54 hours at steady state.
The oral plasma clearance of escitalopram is 600 mL/min, of which approximately 7% is due to renal clearance.
Pregnancy & Breastfeeding use
Pregnancy: The safety of escitalopram during pregnancy and lactation has not been established. Therefore, escitalopram should not be used during pregnancy unless, in the opinion of the physician, the expected benefits to the patient outweigh the possible hazards to the fetus.
Nursing Mothers: Andepram is excreted in human milk. Andepram should not be given to nursing mothers unless, in the opinion of the physician, the expected benefits to the patient outweigh the possible hazards to the child
Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated. Concomitant use in patients taking pimozide is contraindicated. Esita is contraindicated in patients with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients.
Pediatric Use: Safety and effectiveness in children below the age of 18 years have not been established.
Geriatric patients: Andepram pharmocokinetics in subjects age 65 and over were compared to younger subjects in a single and multi-dose study. No overall differences in safety or effectiveness between this group and the younger subjects was observed, but greater sensitivity of some elderly individuals ca
Store in a cool and dry place below 30º C. Protect from light.